Aromatase inhibitors are preferred over tamoxifen for postmenopausal women because a number of studies have shown that postmenopausal women treated with an aromatase inhibitor have a slightly lower recurrence risk than women treated with tamoxifen. The researchers then looked to see if recurrence risk was lower and survival was better in either group of women. The researchers also looked to see if 10 years of tamoxifen caused side effects in any of the women.
This difference was significant, which means that it was likely because of the extra 5 years of tamoxifen and not just due to chance. Like any hormonal therapy medicine, tamoxifen can cause side effects, some of them serious. Hot flashes and night sweats are common tamoxifen side effects.
In rare cases, tamoxifen can cause dangerous blood clots. Tamoxifen also may increase the risk of endometrial cancer in some women. In this study, the researchers found that 10 years tamoxifen increased the risk of endometrial cancer compared to 5 years of tamoxifen. Still, the benefits of taking tamoxifen for 10 years outweighed the risks. Combined with the results of the ATLAS trial, these results are extremely promising and likely to change the hormonal therapy standard of care for women diagnosed with early-stage, estrogen-receptor-positive breast cancer.
Director's Message. Budget Proposal. Stories of Cancer Research. Driving Discovery. Highlighted Scientific Opportunities. Research Grants. Research Funding Opportunities. Cancer Grand Challenges. Research Program Contacts.
Funding Strategy. Grants Policies and Process. Introduction to Grants Process. NCI Grant Policies. Legal Requirements.
Step 3: Peer Review and Funding Outcomes. Manage Your Award. Grants Management Contacts. Prior Approvals. Annual Reporting and Auditing. Transfer of a Grant. Grant Closeout. Cancer Training at NCI. Resources for Trainees. Funding for Cancer Training. Building a Diverse Workforce. National Cancer Act 50th Anniversary Commemoration. Resources for News Media. Media Contacts. Cancer Reporting Fellowships.
Advisory Board Meetings. Social Media Events. Cancer Currents Blog. Contributing to Cancer Research. Strategic Planning. Principal Deputy Director's Page. Previous NCI Directors. NCI Frederick. Advisory Boards and Review Groups. NCI Congressional Justification. Current Congress. Committees of Interest. Legislative Resources. Recent Public Laws. Search Search. Breast Cancer. Breast Cancer Treatment. Male Breast Cancer Treatment. Childhood Breast Cancer Treatment.
Breast Cancer During Pregnancy. Breast Cancer Prevention. If you're taking tamoxifen, call your doctor immediately if you have any of these symptoms:. Hot flashes or night sweats from taking tamoxifen can be troubling. But a British study suggests that women who experienced hot flashes and night sweats while taking hormonal therapy medicine were less likely to have the breast cancer come back recur. Knowing that this side effect might indicate a reduced risk of the cancer coming back may help some people stick with treatment despite the side effects.
Some women on tamoxifen have reported memory problems while taking the medicine. While no definitive results are available yet, the ongoing Co-STAR Cognition in the Study of Tamoxifen and Raloxifene trial is looking at the effects tamoxifen and raloxifene have on memory and thinking. While costs vary, tamoxifen is usually less expensive than an aromatase inhibitor because it is a generic medicine.
If you have health insurance, check with your insurance company to see if and how much of the cost of tamoxifen is covered. If you don't have health insurance or your insurance doesn't cover the cost of tamoxifen, ask your doctor or nurse about programs in your area that may be able to help. Soltamox is available to patients who qualify at the same co-pay cost as generic tamoxifen. You can also read Breastcancer. Create a profile for better recommendations. Breast implant illness BII is a term that some women and doctors use to refer to a wide range Sign up for emails about breast cancer news, virtual events, and more.
Subscribe to our podcast for conversations on the issues that matter most. Join our online community to connect, share, and find peer support. Cell with estrogen receptors blocked by tamoxifen and helper proteins Larger Version.
Was this article helpful?
0コメント